Ikaros Gene Expression and Leukemia

• Published in: Leukemia & lymphoma 2002, Vol.43 (1), p.29-35
• Main Authors: Tonnelle, Cécile, Calmels, Boris, Maroc, Christine, Gabert, Jean, Chabannon, Christian
• Format: Article
• Language: English
• Subjects: Acute Leukemia; Alternative Splicing; Animals; Chronic Leukemia; DNA-Binding Proteins; Gene Expression Regulation, Neoplastic; Humans; Ikaros; Ikaros Transcription Factor; Leukemia - etiology; Leukemia - genetics; Leukemia - pathology; Mutation; Protein Isoforms - genetics; Protein Isoforms - metabolism; Transcription Factor; Transcription Factors - genetics; Transcription Factors - metabolism
• ISSN: 1042-8194; 1029-2403
• DOI: 10.1080/10428190210186

The Ikaros (Ik) protein, or LyF1, was initially described as a protein binding to regulatory sequences of a number of genes expressed in murine lymphoid cells. Ikaros is a critical regulator of normal hematopoietic stem cell differentiation, as evidenced by dramatic defects in the lymphoid compartments, in homozygous animals with gene inactivation. Because differential splicing produces multiple isoforms with potentially different functions, Ikaros provides a unique model to study how post-transcriptional mechanisms may be involved in neoplastic processes. Indeed, several groups including ours have underlined evidences that expression of different Ikaros isoforms vary among different types of leukemias. The predominance of short isoforms in certain subsets is intriguing. Here, additional observations reinforced the hypothesis that Ikaros expression may be deregulated in human leukemias. Whether this is a cause or a consequence of the leukemic process remains speculative. Other human diseases however, provide examples of abnormal post-transcriptional regulations that have been further characterized.